Elecoglipron trial reveals systemic gaps in obesity treatment: Phase 2 results highlight market-driven drug development over structural prevention
Original framing: “[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial” — The Lancet
Future scenarios must account for the unintended consequences of GLP-1 drugs, such as rebound weight gain post-treatment, the environmental cost of pharmaceutical production, and the potential for overmedicalization of a societal issue. Modeling should include the impact of climate change on food systems, which could exacerbate obesity by increasing the cost of fresh foods. Additionally, future health systems must integrate drug therapies with structural interventions like urban farming and school meal programs.
The elecoglipron trial exemplifies how biomedical reductionism obscures the structural roots of obesity, a crisis shaped by colonial food systems, corporate lobbying, and racialized economic disparities.
While the drug may offer short-term relief, it diverts attention from proven systemic solutions like food taxes, community-based nutrition, and urban redesign—interventions that have succeeded in countries like Mexico and New Zealand. The trial’s exclusion of marginalized voices and indigenous knowledge reflects a broader pattern where profit-driven science prioritizes marketable treatments over equitable health outcomes. Hermes’ trickster energy reveals the absurdity of treating a societal ailment with a pill, while future modeling must account for the rebound effects of pharmaceutical interventions and the climate impacts on food systems. True progress requires dismantling the power structures that have commodified food and health, replacing them with policies rooted in equity, ecology, and cultural wisdom.